07:00 , Oct 2, 2008 |  BC Innovations  |  Cover Story

Truly Boronic

Researchers at Tufts University have shown that peptide boronic acid inhibitors of dipeptidyl peptidase-4 could provide effective, low-toxicity treatments for diabetes.1 The findings challenge the long-held assumption that boronic acids are too toxic for therapeutic...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Clinical News

ARI-2243: Phase I start

This half, Arisaph will begin a dose-escalation Phase I trial of oral ARI-2243 given once daily in healthy volunteers. Arisaph Pharmaceuticals Inc., Boston, Mass.   Product: ARI-2243   Business: Endocrine   Molecular target: Dipeptidyl peptidase-4 (DPP-4)...
07:00 , Aug 27, 2007 |  BioCentury  |  Strategy

Targeting DPP-4

Targeting DPP-4 Company Product Status Novartis Galvus vildagliptin (LAF237) FDA approvable letter (resubmit NDA mid-09) AstraZeneca/Bristol-Myers/Otsuka Saxagliptin Ph III (submit NDA 1H08) Takeda Alogliptin (SYR322) [from Syrrx acq] Ph III Phenomix PHX1149 Ph IIb Glenmark/...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

Arisaph preclinical data

In healthy mice, ARI-2243, a dipeptidyl peptidase-4 (DPP-4) inhibitor, lowered plasma glucose levels further than Januvia sitagliptin, an approved DPP-4 inhibitor from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.). In diabetic...